First Eagle Investment Management LLC Has $1.68 Million Holdings in Vascular Biogenics Ltd. (VBLT)

First Eagle Investment Management LLC reduced its stake in Vascular Biogenics Ltd. (NASDAQ:VBLT) by 58.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 274,820 shares of the biopharmaceutical company’s stock after selling 380,754 shares during the quarter. First Eagle Investment Management LLC owned approximately 1.01% of Vascular Biogenics worth $1,676,000 at the end of the most recent quarter.

Separately, KCG Holdings Inc. purchased a new stake in Vascular Biogenics in the 1st quarter valued at $248,000. 8.99% of the stock is currently owned by institutional investors.

Vascular Biogenics Ltd. (VBLT) traded up $0.80 during midday trading on Wednesday, hitting $8.70. The stock had a trading volume of 765,600 shares, compared to its average volume of 135,047. Vascular Biogenics Ltd. has a fifty-two week low of $3.90 and a fifty-two week high of $9.00.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. research analysts predict that Vascular Biogenics Ltd. will post -0.81 earnings per share for the current year.

VBLT has been the subject of several analyst reports. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th. ValuEngine cut Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Friday, September 8th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Vascular Biogenics in a report on Tuesday, November 7th. Finally, Chardan Capital increased their price target on Vascular Biogenics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, November 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Vascular Biogenics presently has an average rating of “Buy” and an average target price of $16.00.

TRADEMARK VIOLATION NOTICE: “First Eagle Investment Management LLC Has $1.68 Million Holdings in Vascular Biogenics Ltd. (VBLT)” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.themarketsdaily.com/2017/11/15/first-eagle-investment-management-llc-has-1-68-million-holdings-in-vascular-biogenics-ltd-vblt.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply